PharmaJet and Genexine collaborate on DNA vaccine development

GOLDEN, Colo. — Feb. 20, 2018 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced a global license agreement with Genexine, a leading biotherapeutics company headquartered in South Korea, for the development and commercialization of DNA vaccines for human applications using the PharmaJet needle-free injection systems. Under the terms of the agreement, Genexine will use both the PharmaJet Stratis® and Tropis® devices in their Phase 1 and IIa human clinical studies. The agreement also includes provision for potential expansion to include Phase III studies and commercialization.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies. DNA vaccines can be used as targeted “therapeutic vaccines” to induce an immune response which can detect and destroy infectious diseases and potentially cancer.1 Genexine’s product pipeline, focused on innovative immunotherapeutics and next generation novel long-acting biologics, includes a vaccine for human papilloma virus (HPV) type 16 and 18 associated cervical intraepithelial neoplasia (CIN), which eventually causes cervical cancer.

“We are pleased to be part of the upcoming clinical trials of these DNA vaccines. Our needle-free technology features a precise and consistent method of delivery, which helps to maximize target gene expression in the human body,” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc. “In addition, it offers benefits over the alternative of electroporation delivery.”

Refer to Instructions for Use to ensure safe injections and to review risks.
1 Therapeutic DNA Vaccine Technology: Immune Enhancing Technology;